• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白联合甲氨蝶呤治疗活动性类风湿关节炎的疗效和安全性的开放多中心临床研究

ReABLE study on the efficacy and long-term safety of recombinant human tumor necrosis factor-α receptor Ⅱ IgG Fc fusion protein with methotrexate in active rheumatoid arthritis

摘要:

目的 评估重组人Ⅱ型肿瘤坏死因子受体—抗体融合蛋白(rhTNRF:Fc)联合甲氨蝶呤治疗活动性类风湿关节炎(RA) 52周的临床疗效、放射学改变和安全性。方法 30例中重度活动性RA患者应用rhTNRF:Fc(25 mg皮下注射,每周2次)联合甲氨蝶呤(每周15 mg口服)治疗。应用美国风湿病学会(ACR)20、50、70疗效标准和28个关节的疾病活动度评分(DAS28)评估临床疗效,应用改良的Sharp评分标准评价放射学疗效。计数资料应用x2检验或Fisher精确检验,计量资料采用配对t检验。结果 治疗52周时达到ACR20、50、70标准的有效率分别为90%、87%和67%。DAS28由6.4±0.6降至3.4±1.1(P<0.01),23%患者达到疾病缓解,17%达到低度活动状态。健康状况问卷由1.18±0.56降至0.25±0.34(P<0.01)。基线期和52周时,双手和双腕X线片关节间隙狭窄(8±10与8±11)和关节侵蚀(10±15与10±15)的改良Sharp评分差异无统计学意义;73%患者无放射学进展。未见严重不良反应,无新发结核菌感染和恶性肿瘤。结论 rhTNRF:Fc联合甲氨蝶呤治疗RA 52周能够显著减低疾病活动度、改善关节功能以及延缓放射学进展,达到临床缓解和阻止放射学进展的治疗目标:且耐受性良好。

更多
abstracts:

Objective To evaluate the clinical and radiographic efficacy and safety of the combination of recombinant human tumor necrosis factor-αt receptor Ⅱ IgG Fc fusion protein (rhTNFR:Fc) and methotrexate (MTX) in patients with rheumatoid arthritis (RA). Methods Thirty patients with highly active RA were treated with rhTNFR:Fc (25 mg subcutaneously twice weekly) and oral MTX (up to 15 mg weekly). Clinical efficacy was assessed using ACR response criteria and the disease activity score in 28 joints (DAS28).Radiographs of the hands and wrists were assessed with the modified Sharp score. Chi-square test, Fisher is exact test and paired t-test were performed. Results At week 52, ACR20, ACR50 and ACR70 responses were achieved by 90%, 87% and 67% respectively. At week 52, mean DAS28 was 3.4±1.1 compared to 6.4±0.6 at base-line (P<0.01), with 23% patients achieving clinical remission and 17% patients in low disease activity. Similarly, the HAQ was improved significantly, declining from 1.18±0.56 at base-line to 0.25t±0.34 at week 52 (P<0.01). No radiographic progression was found in 22 cases. Adverse events were mild in general.Conclusion Treatment with rhTNFR:Fc plus MTX has shown good efficacy throughout 52 study period in reducing disease activity, improving function, and retarding radiographic progression. Combination therapy for 52 weeks can achieve disease remission and no radiographic progression, which are the two goals of therapy for RA.

More
  • 浏览:750
  • 下载:309

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷